Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new eyedrop heal the cornea in dry eye disease?

NCT ID NCT06370039

Symptom relief Sponsor: Invirsa, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are testing an experimental eyedrop called INV-102 in adults with moderate to severe dry eye disease. The trial compares INV-102 with a vehicle drop over four weeks of repeated dosing. The main goal is to see whether INV-102 reduces corneal damage, measured by a standard staining score. About 109 participants will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
INV-102 ophthalmic solution, an experimental eyedrop
What this could lead to
If INV-102 works, it could offer a new eyedrop that helps repair the cornea in people with moderate to severe dry eye disease.
What could go wrong
This is a Phase 2 trial with about 109 participants, so it may not show a clear benefit or the results may not hold in larger studies. Eyedrops can cause stinging, irritation, or other eye side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

109 people

The number who actually took part.

Started

Mar 2024

Finished

Jul 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 74 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Subjects ≥18 and \<75 years of age * Presence of moderate to severe dry eye disease (DED) in at least one eye Key Exclusion Criteria: * Presently using prescription eyedrops, except those used for dry eye disease, which must be discontinued 4 weeks prior * Use of over-the-counter (OTC) eyedrops except for lubricant eyedrops or artificial tears, within 1 week prior to initiation of study drug dosing * History or evidence of ocular infection within the previous 30 days * Blepharitis or meibomian gland disease requiring the use of either topical or systemic antibiotics within 2 months * Allergic conjunctivitis requiring treatment within 30 days * Unable to discontinue contact lens wear for 2 weeks prior and for the duration of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye disease

Contacts and locations

Locations

  • iuvo BioScience

    Rush, New York, 14543, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.